BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 23082737)

  • 1. Melanoma brain metastasis: overview of current management and emerging targeted therapies.
    Fonkem E; Uhlmann EJ; Floyd SR; Mahadevan A; Kasper E; Eton O; Wong ET
    Expert Rev Neurother; 2012 Oct; 12(10):1207-15. PubMed ID: 23082737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic treatment of melanoma brain metastases].
    Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
    Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapies in melanoma.
    Scheier B; Amaria R; Lewis K; Gonzalez R
    Immunotherapy; 2011 Dec; 3(12):1461-9. PubMed ID: 22091682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing melanoma therapeutics: overview and update.
    Korman JB; Fisher DE
    Wiley Interdiscip Rev Syst Biol Med; 2013; 5(3):257-71. PubMed ID: 23408545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BRAF mutation: a novel approach in targeted melanoma therapy].
    Arenbergerová M; Puzanov I
    Klin Onkol; 2012; 25(5):323-8. PubMed ID: 23102192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM; Margolin K
    Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
    Dean E; Lorigan P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.
    Long GV; Margolin KA
    Am Soc Clin Oncol Educ Book; 2013; ():393-8. PubMed ID: 23714558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapies for melanoma brain metastases: which drug for whom and when?
    Ramanujam S; Schadendorf D; Long GV
    Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib for the treatment of melanoma.
    Jordan EJ; Kelly CM
    Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.
    Grimaldi AM; Simeone E; Palla M; Festino L; Caracò C; Mozzillo N; Petrillo A; Muto P; Ascierto PA
    Anticancer Drugs; 2015 Apr; 26(4):464-8. PubMed ID: 25622086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strides in melanoma announced: maximizing value comes next.
    Tuma RS
    J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
    [No Abstract]   [Full Text] [Related]  

  • 15. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.
    Forschner A; Niessner H; Bauer J; Bender B; Garbe C; Meier F
    JAMA Dermatol; 2013 May; 149(5):642-4. PubMed ID: 23677116
    [No Abstract]   [Full Text] [Related]  

  • 17. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
    D'Alonzo D; Glatz K
    Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
    [No Abstract]   [Full Text] [Related]  

  • 18. [Major therapeutic advances in the treatment of metastatic melanoma].
    Mateus C; Robert C
    Bull Cancer; 2012 Jun; 99(6):619-25. PubMed ID: 22652330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of systemic therapies in the management of melanoma brain metastases.
    Lyle M; Long GV
    Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.